We are live on ! Find out more
CNTA

Centessa Pharmaceuticals

Delisted

CNTA was delisted on the 23rd of June, 2026.

80 hedge funds and large institutions have $781M invested in Centessa Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

341% more call options, than puts

Call options by funds: $119K | Put options by funds: $27K

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

42% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 19

16% more funds holding

Funds holding: 6980 (+11)

0.33% more ownership

Funds ownership: 76.2%76.53% (+0.33%)

0% more funds holding in top 10

Funds holding in top 10: 55 (0)

7% less capital invested

Capital invested by funds: $841M → $781M (-$59.5M)

Holders
80
Holders Change
+11
Holders Change %
+15.94%
% of All Funds
1.15%
Holding in Top 10
5
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.07%
New
17
Increased
27
Reduced
19
Closed
6
Calls
$119K
Puts
$27K
Net Calls
+$92K
Net Calls Change
-$47K
Name Holding Trade Value Shares
Change
Change in
Stake
BBA
26
Baker Bros. Advisors
New York
$4.96M +$5.21M +549,212 New
PIM
27
Platinum Investment Management
Australia
$4.48M +$102K +10,721 +2%
BlackRock
28
BlackRock
New York
$4.2M +$779K +82,160 +21%
NCM
29
Nantahala Capital Management
Connecticut
$4.06M +$4.27M +450,000 New
TD Asset Management
30
TD Asset Management
Ontario, Canada
$2.9M +$878K +92,524 +40%
EAM
31
Exome Asset Management
New York
$2.48M
ACM
32
ADAR1 Capital Management
Texas
$2.29M +$440K +46,341 +22%
Marshall Wace
33
Marshall Wace
United Kingdom
$2.03M -$62.8K -6,617 -3%
Renaissance Technologies
34
Renaissance Technologies
New York
$1.57M -$428K -45,100 -21%
Manulife (Manufacturers Life Insurance)
35
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.27M +$312K +32,846 +30%
WP
36
Woodline Partners
California
$1.11M +$1.17M +123,461 New
DCM
37
DAFNA Capital Management
California
$1.11M +$1.17M +122,882 New
MIM
38
Monashee Investment Management
Massachusetts
$932K +$979K +103,191 New
HWM
39
HighMark Wealth Management
Minnesota
$840K +$882K +93,000 New
ECM
40
ExodusPoint Capital Management
New York
$788K -$2.77M -292,104 -77%
Bank of America
41
Bank of America
North Carolina
$662K -$35.2K -3,707 -5%
PCM
42
Prelude Capital Management
New York
$622K -$1.98K -209 -0.3%
GCP
43
GSA Capital Partners
United Kingdom
$509K +$406K +42,796 +315%
Two Sigma Investments
44
Two Sigma Investments
New York
$468K -$256K -26,981 -34%
Millennium Management
45
Millennium Management
New York
$447K -$2.26M -237,908 -83%
TI
46
Trexquant Investment
Connecticut
$395K -$501K -52,783 -55%
Citadel Advisors
47
Citadel Advisors
Florida
$346K -$82.4K -8,692 -19%
Geode Capital Management
48
Geode Capital Management
Massachusetts
$303K
RG
49
Rathbones Group
United Kingdom
$283K
CSS
50
Cubist Systematic Strategies
Connecticut
$235K -$441K -46,536 -64%

CNTA Hedge Fund Activity: Q2 2024 in Review

80 of the 6,928 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q2 2024, worth a combined $781M — down 7.1% from $841M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new CNTA positions and 6 closed out — a net gain of 11 holders — while 27 added to existing stakes and 19 trimmed.

The largest buyer was First Light Asset Management, adding an estimated $16.9M. The largest seller was Point72 Asset Management, cutting an estimated $4.7M.

  • 80 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q2 2024, up from 69 in Q1 2024.
  • Funds reported $781M of Centessa Pharmaceuticals stock for Q2 2024, down 7.1% quarter-over-quarter.
  • 17 funds opened new Centessa Pharmaceuticals positions in Q2 2024 and 6 closed out, a net change of +11 holders.
  • The largest Centessa Pharmaceuticals buyer in Q2 2024 was First Light Asset Management, an estimated $16.9M added.
  • The largest Centessa Pharmaceuticals seller in Q2 2024 was Point72 Asset Management, an estimated $4.7M sold.

Based on aggregated 13F filings for Q2 2024.